Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 15, 2026 | June 17, 2026 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | SVP, Head of Global Commercial | March 26, 2019 | March 27, 2019 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,500 |
Ending reported balance
After 2026-06-17 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-06-15 · Exercise / conversion · Acquired 6,460 · Balance 54,760 Row 2 · 2026-06-15 · Sale · Disposed 6,460 · Balance 48,300 Row 3 · 2026-06-16 · Sale · Disposed 12,800 · Balance 35,500 F1: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-06-17 · Exercise / conversion · Acquired 13,040 · Balance 48,540 Row 5 · 2026-06-17 · Sale · Disposed 13,040 · Balance 35,500 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-06-04 | Direct | 13,040 |
Reported balance
After 2026-06-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-15 · Exercise / conversion · Disposed 6,460 · Balance 13,040 F2: The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-06-04 | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-17 · Exercise / conversion · Disposed 13,040 · Balance 0 F2: The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.
Atara Biotherapeutics, Inc.
Report date March 26, 2019 · Filed March 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,688 |
Reported balance
After 2019-03-26 transaction · row 1
1 source rowRow 1 · 2019-03-26 · Grant · Acquired 10,000 · Balance 31,688 F1: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionStock Option (right to buy) · Derivative | 13,040 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · derivative · entry 7 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,040 shares Expires 2035-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 13,040 | $2.33 | $30,318.00 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · nonDerivative · entry 5 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 13,040 | $1.07 | $13,952.80 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · nonDerivative · entry 4 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 12,800 | $2.33 | $29,772.80 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · nonDerivative · entry 3 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 F1 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionStock Option (right to buy) · Derivative | 6,460 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · derivative · entry 6 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,040 Underlying: Common Stock · 6,460 shares Expires 2035-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 6,460 | $2.35 | $15,148.70 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · nonDerivative · entry 2 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,300 Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 6,460 | $1.07 | $6,912.20 |
DisclosureSEC source: 0001628280-26-043987 · wk-form4_1781730613.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 53,250 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001628280-26-041272 · wk-form4_1780691403.xml · derivative · entry 2 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,250 Underlying: Common Stock · 53,250 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041272 · wk-form4_1780691403.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,300 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:13 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 10,539 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001706400-26-000002 · form4-05212026_080536.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,539 Underlying: Common Stock · 10,539 shares Expires 2036-05-19 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001576885-25-000078 · wk-form4_1749156630.xml · derivative · entry 2 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000078 · wk-form4_1749156630.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 23:29 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 201,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-25-015057 · form4-05302025_110521.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,857 Underlying: Common Stock · 201,857 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 20:46 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001576885-24-000080 · wk-form4_1718052386.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:51 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 47,693 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-24-014309 · form4-05232024_080531.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,693 Underlying: Common Stock · 47,693 shares Expires 2034-05-21 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 21:43 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001576885-23-000035 · wk-form4_1686174215.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:35 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032568 · doc4.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 00:41 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option Grant (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001209191-23-001431 · doc4.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-04 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:32 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-22-032837 · doc4.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| May 27, 2021 Filed May 28, 2021 21:56 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 33,836 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001209191-21-036621 · doc4.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,836 Underlying: Common Stock · 33,836 shares Expires 2031-05-26 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 21:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021441 · doc4.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,688 F1 · shares: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001209191-19-011175 · doc4.xml · derivative · entry 3 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,666 Underlying: Common Stock · 4,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018. F2 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,909 | $40.00 | $236,360.00 |
DisclosureSEC source: 0001209191-19-011175 · doc4.xml · nonDerivative · entry 2 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,688 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,000 | $14.30 | $57,200.00 |
DisclosureSEC source: 0001209191-19-011175 · doc4.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 24,625 | $0.00 Strike: $38.47 | $0.00 |
DisclosureSEC source: 0001209191-19-008508 · doc4.xml · derivative · entry 3 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,625 Underlying: Common Stock · 24,625 shares Expires 2029-02-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 12,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008508 · doc4.xml · nonDerivative · entry 2 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,597 F2 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 1,216 | $38.47 | $46,779.52 |
DisclosureSEC source: 0001209191-19-008508 · doc4.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,284 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:41 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,334 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001209191-18-030727 · doc4.xml · derivative · entry 3 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,666 Underlying: Common Stock · 16,334 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 9, 2018. F3 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:41 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 16,334 | $45.02 | $735,356.68 |
DisclosureSEC source: 0001209191-18-030727 · doc4.xml · nonDerivative · entry 2 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 9, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $45.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:41 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 16,334 | $14.30 | $233,576.20 |
DisclosureSEC source: 0001209191-18-030727 · doc4.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 9, 2018. Read SEC document |
| May 08, 2018 Filed May 9, 2018 00:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,544 | $40.15 | $61,991.60 |
DisclosureSEC source: 0001209191-18-028714 · doc4.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 9, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-18-008510 · doc4.xml · derivative · entry 2 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-02-06 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008510 · doc4.xml · nonDerivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,044 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. F2 · balance_after: Includes 1,544 shares issued on November 30, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 10, 2017 Filed May 11, 2017 23:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001209191-17-031664 · doc4.xml · derivative · entry 1 Porter Derrell · CIK 0001706400 · SVP, Head of Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2024-05-10 F1 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.